Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio

Everest Medicines has secured exclusive rights to develop and commercialize sumecigrel across the Asia-Pacific region. This agreement with Jiangsu Vcare Pharmaceutical marks a significant expansion of Everest Medicines' cardiovascular drug offerings.

The drug, sumecigrel, is currently undergoing clinical trials and is intended for the treatment of cardiovascular diseases. The licensing deal grants Everest Medicines the sole authority to market and sell the compound in the specified territories.

This licensing agreement strengthens Everest Medicines' position in the cardiovascular market by adding a promising new drug candidate to its pipeline.